PFIZi014-A

OD002-s7

iPSC line

At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: 48hr post thaw
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg Name PFIZi014-A
Alternative name(s)
OD002-s7
Cell line type Human induced pluripotent stem cell (hiPSC)

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)

External Databases

hPSCreg PFIZi014-A
BioSamples SAMEA4454946
Cellosaurus CVCL_IJ01
ECACC 66540375
CLO CLO_0101602
Wikidata Q54947269

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information#

General Donor Information

Sex male
Age of donor (at collection) 10-14

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Dravet syndrome
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
NM_006920.4:c.1112C>T
Heterozygous
SCV000242490.10
Transition C>T; nucleotide position: 1112; codon: 371; Amino Acid Change - Ala to Val
Disease associated phenotypes
  • Generalized epilepsy
  • Developmental delays
  • Station and gait are slightly wide based

External Databases (Donor)

BioSamples SAMEA4454945

hIPSC Derivation#

General

Source cell type
erythroblast
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Source cell type (free text) PBMC erythroblasts
Age of donor (at collection) 10-14

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
No
Available as clinical grade?
Unknown

Culture Conditions#

Latest released batch

Culture medium Essential 8
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
SSEA-1
No
TRA 1-81
Yes
SSEA-4
Yes
Self-renewal
Negative
Endoderm
Unknown
Mesoderm
Unknown
Ectoderm score
Unknown
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Scorecard
Mesoderm
Ont Id: UBERON_0000926
Scorecard
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Scorecard

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome abnormalities detected
Passage number: 16
Karyotyping method: BoBs

Other Genotyping (Cell Line)